Today I had a chat with Nigel Theabold CEO of N4 Pharma, the small private company hit the headlines when Aim listed investment company Onzima Ventures announced its investment for 49% of the company. The business works extensively on a number of compounds through the early development stage, with a novel structure which reduces significant dilution whilst focusing on progressing quickly into presenting its products through its technology platform.
- Business model to reformulate and develop erectile dysfunction drugs
- Strong background in product development working with Oxford Pharma Science
- New clinical and commercial products into the forefront of industry
- Regular focus on news flow with as the exciting outlook surfaces further